DEF 14A: Krystal Biotech Announces 2024 Annual Meeting of Stockholders

Krystal Biotech will hold its 2024 annual meeting of stockholders virtually on May 17, 2024, to vote on director elections, auditor ratification, and executive compensation.

Summary

• Krystal Biotech will hold its 2024 annual meeting of stockholders virtually on May 17, 2024, at 4:00 p.m. Eastern Time.
• Stockholders will vote on the election of three Class I director nominees, the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and a non-binding, advisory vote on the compensation of named executive officers.
• The record date for determining stockholders eligible to vote is March 25, 2024.
• Proxy materials are available online, and stockholders can vote via the Internet, telephone, or by returning a proxy card.
• The Board of Directors recommends voting FOR the election of the director nominees, FOR the ratification of KPMG, and FOR the approval of the compensation of named executive officers.

Sentiment

Score: 8

Explanation: The document is positive due to the FDA approval and successful launch of VYJUVEK, strong financial performance, and progress in the clinical pipeline.

Positives

• The Board recommends voting FOR all proposals.
• Krystal Biotech's first commercial product, VYJUVEK, was approved by the FDA on May 19, 2023, and launched in the U.S. soon thereafter for the treatment of DEB, a serious rare skin disease caused by missing or mutated COL7 protein.
• VYJUVEK achieved $50.7 million in net product revenue for 2023.
• Gross margins for VYJUVEK were 93% in the fourth quarter of 2023.
• Patient compliance to once weekly treatment while on VYJUVEK was strong and sustained, with a 96% compliance rate for 2023.
• The company sold a Rare Pediatric Disease Voucher in the third quarter of 2023 for $100.0 million.
• The company ended 2023 with cash, cash equivalents and investments of $594.1 million.

Future Outlook

The company expects an EMA decision on its MAA for B-VEC in the second half of 2024 and anticipates filing a Japan New Drug Application in the second half of 2024 enabling a potential authorization in 2025.

Industry Context

Krystal Biotech is operating in the competitive gene therapy space, focusing on rare diseases with high unmet medical needs. The approval and launch of VYJUVEK positions them as a key player in redosable gene therapies.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document does mention that the compensation peer group consists of biotechnology and pharmaceutical companies that are similar to Krystal Biotech in terms of market capitalization and stage of development.
• These companies include Agios Pharmaceuticals, BridgeBio Pharma, Intra-Cellular Therapies, Alector, Crinetics Pharmaceuticals, Mirati Therapeutics, AlloVir, Cytokinetics, REGENXBIO, Apellis Pharmaceuticals, Denali Therapeutics, Sorrento Therapeutics, BioCryst Pharmaceuticals, ImmunityBio, SpringWorks Therapeutics, Blueprint Medicines, and Insmed.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key company matters.
• Patients with DEB now have access to a new treatment option with VYJUVEK.
• Employees are part of a growing company with a commercial product and a robust pipeline.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will continue to pursue regulatory approvals for B-VEC in Europe and Japan.
• The company plans to initiate a clinical study of ophthalmic B-VEC in the second half of 2024.
• The company plans on initiating the KYANITE-1 study in the first half of 2024.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Krystal Biotech, Stockholders, Directors, Executive Compensation, KPMG, Voting, VYJUVEK, DEB, Gene Therapy